An official website of the United States government
Home
Name
Belzutifan
Alternate Names
Welireg
Abbreviations
None
Category
Chemotherapy
Subcategory
Hypoxia-inducible factor inhibitor
NSC Number
None
Primary Site
Histology
RCC, hemangioblastoma, pNET, pheochromocytoma
Remarks
On May 14, 2025, the FDA approved belzutifan (Welireg, Merck & Co., Inc.) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.
December 14, 2023 The FDA approved belzutifan (Welireg,) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
August 13, 2021 The FDA approved belzutifan (Welireg), a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
December 14, 2023 The FDA approved belzutifan (Welireg,) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
August 13, 2021 The FDA approved belzutifan (Welireg), a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Coding
This drug should be coded
